AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD

DOI: 10.1038/sj.bjc.6603170
Published: 2006 Jun 19
Container: British journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/sj.bjc.6603170,
  title = {AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.},
  author = {Weisberg E and Manley P and Mestan J and Cowan-Jacob S and Ray A and Griffin JD},
  year = {2006},
  journal = {British journal of cancer},
  doi = {10.1038/sj.bjc.6603170},
  url = {https://doi.org/10.1038/sj.bjc.6603170}
}

RIS

TY  - JOUR
TI  - AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
AU  - Weisberg E
AU  - Manley P
AU  - Mestan J
AU  - Cowan-Jacob S
AU  - Ray A
AU  - Griffin JD
PY  - 2006
JO  - British journal of cancer
DO  - 10.1038/sj.bjc.6603170
UR  - https://doi.org/10.1038/sj.bjc.6603170
ER  -

APA

E, W., P, M., J, M., S, C., A, R., & JD, G. (2006). AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.. British journal of cancer. https://doi.org/10.1038/sj.bjc.6603170

Source records

pubmed · retrieved 2026-09-25T23:58:11.545Z